ApoE抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using ApoE mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues (left) and brain tissues (right) using ApoE mouse mAb with DAB staining.    

  
  

Apolipoprotein E (ApoE) is a lipid-binding protein critical for lipid metabolism and neuronal repair. It exists in three major isoforms (ApoE2. ApoE3. ApoE4), with the ε4 allele strongly linked to Alzheimer’s disease (AD) risk. ApoE antibodies are tools developed to study ApoE’s role in health and disease. These antibodies enable detection of ApoE expression, isoform-specific interactions, and distribution in tissues, particularly the brain. In AD research, they help investigate ApoE’s involvement in amyloid-beta plaque clearance, tau pathology, and neuroinflammation.

Monoclonal and polyclonal ApoE antibodies are widely used in techniques like ELISA, Western blot, and immunohistochemistry. Isoform-specific antibodies (e.g., targeting ApoE4) are vital for studying its pathogenic mechanisms, such as impaired lipid transport and enhanced amyloid aggregation. Therapeutic strategies also explore ApoE-targeting antibodies to modulate ApoE function, promote amyloid clearance, or block harmful isoform effects.

However, challenges remain, including cross-reactivity between isoforms and variability in antibody performance across experimental models. Recent advances in antibody engineering aim to improve specificity and develop clinical-grade reagents for diagnostic or therapeutic applications. Overall, ApoE antibodies remain indispensable for unraveling ApoE-related pathways and advancing AD therapeutics.